501 related articles for article (PubMed ID: 27057469)
1. Trial Watch-Oncolytic viruses and cancer therapy.
Pol J; Buqué A; Aranda F; Bloy N; Cremer I; Eggermont A; Erbs P; Fucikova J; Galon J; Limacher JM; Preville X; Sautès-Fridman C; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Feb; 5(2):e1117740. PubMed ID: 27057469
[TBL] [Abstract][Full Text] [Related]
2. Trial watch: Oncolytic viruses for cancer therapy.
Vacchelli E; Eggermont A; Sautès-Fridman C; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Jun; 2(6):e24612. PubMed ID: 23894720
[TBL] [Abstract][Full Text] [Related]
3. Trial Watch:: Oncolytic viruses for cancer therapy.
Pol J; Bloy N; Obrist F; Eggermont A; Galon J; Cremer I; Erbs P; Limacher JM; Preville X; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e28694. PubMed ID: 25097804
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
6. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG; Lévesque S; Workenhe ST; Gujar S; Le Boeuf F; Clements DR; Fahrner JE; Fend L; Bell JC; Mossman KL; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2018; 7(12):e1503032. PubMed ID: 30524901
[TBL] [Abstract][Full Text] [Related]
7. Talimogene Laherparepvec: First Global Approval.
Greig SL
Drugs; 2016 Jan; 76(1):147-54. PubMed ID: 26620366
[TBL] [Abstract][Full Text] [Related]
8. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
10. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
11. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
Zhang Y; Liu Z
Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
14. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
Zheng M; Huang J; Tong A; Yang H
Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
[TBL] [Abstract][Full Text] [Related]
16. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
17. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
18. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM; Westbrook B; McKee S; Norwood TG
Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
[TBL] [Abstract][Full Text] [Related]
20. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
Cassidy T; Craig M
PLoS Comput Biol; 2019 Nov; 15(11):e1007495. PubMed ID: 31774808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]